Bentham Science Logo

Clinical Cancer Drugs

Volume 6, 2 Issues, 2019
ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)
This journal supports open access

Aims & Scope

Clinical Cancer Drugs publishes original research, full-length reviews/ mini reviews, and thematic issues in all core areas of translational and clinical cancer drug research.

The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs, research methodologies, and analyses. The journal is essential reading for clinical oncologists, toxicologists, medicinal chemists, and pharmacologists.

Clinical Cancer Drugs

,

Volume 6

-

Number 1



Preface   Open Access



Biography   Open Access



Review Article   Open Access



Review Article   Open Access



Research Article   Open Access

Evaluation of Fibrolytic Effect of Bauhinia purpurea L.

, 6(1): 21 - 32

Jeevan R. Dash, Tapas K. Sar*, Rinku Buragohain, Indranil Samanta and Rahul Nanotkar


DOI: 10.2174/2212697X06666190131155256


Research Article   Open Access



Research Article   Open Access



Case Report   Open Access



Articles Ahead of Print


Complexity in Clinical Trials: Blind Spots, Misleading Criteria; Winners and Losers


Gang Yuan*, Lishi Wang*, Jing Li, Helin Feng, Jiafu Ji, Weikuan Gu and Baoen Shan


DOI: 10.2174/2212697X06666191021125423
View Abstract




Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil


Neslisah BARLAK, Fatma SANLI, Ozel CAPIK, Elanur TUYSUZ, Elanur AYDIN KARATAS , Hasan TURKEZ and Omer Faruk KARATAS*


DOI: 10.2174/2212697X06666190906165309
View Abstract



Abstracts Ahead of Print

There are currently no Abstracts Ahead of Print available for this journal.

Editor's Choice



Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors

, 2018; 5(1): 28 - 41

Atasi De Chatterjee, Debarshi Roy, Priscilla Guevara, Rituraj Pal, Mahesh Narayan, Sukla Roychowdhury and Siddhartha Das*


DOI: 10.2174/2212697X05666180418145601



Prevalence of Neuropathy Associated With Bortezomib: A Retrospective Study

, 2017; 4(1): 69 - 72

Pulivarthi Swaroopa, Mathew Josy, Ehresmann Kirsten and Gurram Murali Krishna*


DOI: 10.2174/2212697X03666161128102453





Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy

, 2015; 2(1): 61 - 70

Kelly Lien, Michelle Rocha, Elisa Tran, Van C. Hoang, Annabelle Chow and Urban Emmenegger


DOI: 10.2174/2212697X02666150331202809



Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy

, 2014; 1(2): 116 - 126

Annabelle Chow, Giulio Francia, Andrew Kouri, Christina Lee, John M. Ebos, Robert S. Kerbel and Urban Emmenegger


DOI: 10.2174/2212697X01666131218235200



The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment

, 2014; 1(1): 65 - 71

Bianca Maria Veneziani, Micaela Montanari, Maria Letizia Cataldo, Luigi Coppola, Agostina Nardone, Sara Corvigno, Carmine De Angelis, Grazia Arpino, Mario Giuliano, Chiara Carlomagno, Roberto Bianco and Sabino De Placido


DOI: 10.2174/2212697X113016660008



Open Access Articles


Head and Neck Cancer with Lung Metastases: Treatment Challenges

, 2019; 6(1): 48 - 53

Selvamalar Vengathajalam* and Norhafiza Mat Lazim







Evaluation of Fibrolytic Effect of Bauhinia purpurea L.

, 2019; 6(1): 21 - 32

Jeevan R. Dash, Tapas K. Sar*, Rinku Buragohain, Indranil Samanta and Rahul Nanotkar




Metformin Treatment Sensitizes Human Laryngeal Cancer Cell Line Hep- 2 to 5-Fluorouracil

, 2019; 6: 1 - 9 (E-Pub Ahead of Print)

Neslisah BARLAK, Fatma SANLI, Ozel CAPIK, Elanur TUYSUZ, Elanur AYDIN KARATAS , Hasan TURKEZ and Omer Faruk KARATAS*




The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer

, 2019; 6: 1 - 19 (E-Pub Ahead of Print)

Hemantkumar Patadia, Ankita Priyadarshini, Jay Ranade and Ajit Gangawane*




Complexity in Clinical Trials: Blind Spots, Misleading Criteria; Winners and Losers

, 2019; 6: 1 - 13 (E-Pub Ahead of Print)

Gang Yuan*, Lishi Wang*, Jing Li, Helin Feng, Jiafu Ji, Weikuan Gu and Baoen Shan




Clinical Impact of Gastric Acid Suppressants Use on the Efficacy of Gefitinib in Patients with Advanced Adenocarcinoma of the Lung Harboring Common EGFR Mutations

, 2019; 6: 1 - 5 (E-Pub Ahead of Print)

Wang Chun Kwok, James Chung Man Ho, David Chi Leung Lam, Macy Mei Sze Lui, Mary Sau Man Ip and Terence Chi Chun Tam*




Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways

, 2019; 6: 1 - 14 (E-Pub Ahead of Print)

Reena Kasi, Pei Ling Yeo, Khuen Yen Ng, Rhun Yian Koh, Gnanajothy Ponnudurai, Yee Lian Tiong and Soi Moi Chye*







New Robotic Technologies in Cancer Colon Screening

, 2018; 5(2): 68 - 74

Luigi Manfredi* and Gianfranco Natale





Most Cited Articles

Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?

, 2017; 4(2): 74-81.

Manon Launay, Joseph Ciccolini*, Anne Rodallec, Claire Fournel, Florence Duffaud, Sebastien Salas and Bruno Lacarelle


DOI: 10.2174/2212697X04666170531080625


The PI3K/AKT/mTOR-Signal Transduction Pathway as Drug Target in Triple-Negative Breast Cancer

, 2017; 4(1): 47-58.

Jens C. Hahne*, Jorg B. Engel, Arnd Honig, Susanne R. Meyer, Domenico Zito, Andrea Lampis and Nicola Valeri


DOI: 10.2174/2212697X04666170321112629


Intra-arterial Temozolomide, Osmotic Blood-brain Barrier Disruption and Radiotherapy in a Rat F98-Glioma Model

, 2017; 4(2): 135-144.

Annie I. Drapeau, Marie-Belle Poirier, Guru-Swamy Madugundu, J. Richard Wagner and David Fortin*


DOI: 10.2174/2212697X04666170727152212


Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World

, 2017; 4(2): 82-92.

Antonello Di Paolo*, Marzia Del Re, Elena Arrigoni, Teresa Di Desidero, Eleonora Rofi, Romano Danesi and Guido Bocci


DOI: 10.2174/2212697X04666170817124625



Most Accessed Articles

Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 1 – Where Do We Stand?

, 2017; 4(2): 74-81.

Manon Launay, Joseph Ciccolini*, Anne Rodallec, Claire Fournel, Florence Duffaud, Sebastien Salas and Bruno Lacarelle


DOI: 10.2174/2212697X04666170531080625





Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World

, 2017; 4(2): 82-92.

Antonello Di Paolo*, Marzia Del Re, Elena Arrigoni, Teresa Di Desidero, Eleonora Rofi, Romano Danesi and Guido Bocci


DOI: 10.2174/2212697X04666170817124625




Prevention of Capecitabine Toxicity Using a 5-FU Test Dose

, 2017; 4(2): 112-121.

Teresa Di Desidero, Cecilia Barbara, Paola Orlandi, Anna Fioravanti, Fotios Loupakis, Chiara Cremolini, Giacomo Allegrini, Antonello Di Paolo, Alfredo Falcone, Romano Danesi and Guido Bocci*


DOI: 10.2174/2212697X04666170504144550






Editor-in-Chief

Giulio Francia
The University of Texas
El Paso, TX
USA

Biography View Full Editorial Board

Journal History

Clinical Cancer Drugs was introduced in 2014 with the assistance of Dr. Giulio Francia, who is the current Editor-in-Chief serving since 2014.
Track Your Manuscript:


Related Journals

Related eBooks

eBooks Catalog